These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 24048387)

  • 1. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.
    Baune BT; Caliskan S; Todder D
    Hum Psychopharmacol; 2007 Jan; 22(1):1-9. PubMed ID: 17191266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine in combination with citalopram in patients with unipolar psychotic depression.
    Konstantinidis A; Hrubos W; Nirnberger G; Windhager E; Lehofer M; Aschauer H; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):242-7. PubMed ID: 16962224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M;
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.